173 related articles for article (PubMed ID: 36828409)
1. A Computational Inter-Species Study on Safrole Phase I Metabolism-Dependent Bioactivation: A Mechanistic Insight into the Study of Possible Differences among Species.
Pedroni L; Louisse J; Punt A; Dorne JLCM; Dall'Asta C; Dellafiora L
Toxins (Basel); 2023 Jan; 15(2):. PubMed ID: 36828409
[TBL] [Abstract][Full Text] [Related]
2. A computational study on the biotransformation of alkenylbenzenes by a selection of CYPs: Reflections on their possible bioactivation.
Pedroni L; Louisse J; Dorne JCM; Dall'Asta C; Dellafiora L
Toxicology; 2023 Apr; 488():153471. PubMed ID: 36863505
[TBL] [Abstract][Full Text] [Related]
3. Human cytochrome p450 enzyme specificity for the bioactivation of estragole and related alkenylbenzenes.
Jeurissen SM; Punt A; Boersma MG; Bogaards JJ; Fiamegos YC; Schilter B; van Bladeren PJ; Cnubben NH; Rietjens IM
Chem Res Toxicol; 2007 May; 20(5):798-806. PubMed ID: 17407329
[TBL] [Abstract][Full Text] [Related]
4. Physiologically based biokinetic (PBBK) model for safrole bioactivation and detoxification in rats.
Martati E; Boersma MG; Spenkelink A; Khadka DB; Punt A; Vervoort J; van Bladeren PJ; Rietjens IM
Chem Res Toxicol; 2011 Jun; 24(6):818-34. PubMed ID: 21446753
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in silico study on consequences of combined exposure to the food-borne alkenylbenzenes estragole and safrole.
Yang S; Kawai T; Wesseling S; Rietjens IMCM
Toxicol In Vitro; 2022 Mar; 79():105290. PubMed ID: 34861381
[TBL] [Abstract][Full Text] [Related]
6. Human cytochrome p450 enzyme specificity for bioactivation of safrole to the proximate carcinogen 1'-hydroxysafrole.
Jeurissen SM; Bogaards JJ; Awad HM; Boersma MG; Brand W; Fiamegos YC; van Beek TA; Alink GM; Sudhölter EJ; Cnubben NH; Rietjens IM
Chem Res Toxicol; 2004 Sep; 17(9):1245-50. PubMed ID: 15377158
[TBL] [Abstract][Full Text] [Related]
7. 32P-post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. I. Adult female CD-1 mice.
Randerath K; Haglund RE; Phillips DH; Reddy MV
Carcinogenesis; 1984 Dec; 5(12):1613-22. PubMed ID: 6499112
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity studies of the carcinogenicities in the mouse and rat of some naturally occurring and synthetic alkenylbenzene derivatives related to safrole and estragole.
Miller EC; Swanson AB; Phillips DH; Fletcher TL; Liem A; Miller JA
Cancer Res; 1983 Mar; 43(3):1124-34. PubMed ID: 6825084
[TBL] [Abstract][Full Text] [Related]
9. Flavonoids and alkenylbenzenes: mechanisms of mutagenic action and carcinogenic risk.
Rietjens IM; Boersma MG; van der Woude H; Jeurissen SM; Schutte ME; Alink GM
Mutat Res; 2005 Jul; 574(1-2):124-38. PubMed ID: 15914212
[TBL] [Abstract][Full Text] [Related]
10. Physiologically based biokinetic (PBBK) modeling of safrole bioactivation and detoxification in humans as compared with rats.
Martati E; Boersma MG; Spenkelink A; Khadka DB; van Bladeren PJ; Rietjens IM; Punt A
Toxicol Sci; 2012 Aug; 128(2):301-16. PubMed ID: 22588462
[TBL] [Abstract][Full Text] [Related]
11. Occurrence of Alkenylbenzenes in Plants: Flavours and Possibly Toxic Plant Metabolites.
Götz ME; Eisenreich A; Frenzel J; Sachse B; Schäfer B
Plants (Basel); 2023 May; 12(11):. PubMed ID: 37299054
[TBL] [Abstract][Full Text] [Related]
12. 32P-post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. II. Newborn male B6C3F1 mice.
Phillips DH; Reddy MV; Randerath K
Carcinogenesis; 1984 Dec; 5(12):1623-8. PubMed ID: 6499113
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human cytochrome P450 enzymes by the natural hepatotoxin safrole.
Ueng YF; Hsieh CH; Don MJ
Food Chem Toxicol; 2005 May; 43(5):707-12. PubMed ID: 15778010
[TBL] [Abstract][Full Text] [Related]
14. Alkenylbenzenes in Foods: Aspects Impeding the Evaluation of Adverse Health Effects.
Eisenreich A; Götz ME; Sachse B; Monien BH; Herrmann K; Schäfer B
Foods; 2021 Sep; 10(9):. PubMed ID: 34574258
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based kinetic modeling of the bioactivation of myristicin.
Al-Malahmeh AJ; Al-Ajlouni A; Wesseling S; Soffers AE; Al-Subeihi A; Kiwamoto R; Vervoort J; Rietjens IM
Arch Toxicol; 2017 Feb; 91(2):713-734. PubMed ID: 27334372
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of safrole in HepaRG cells: studies on the role of CYP1A2-mediated ortho-quinone metabolic activation.
Hu L; Wu F; He J; Zhong L; Song Y; Shao H
Xenobiotica; 2019 Dec; 49(12):1504-1515. PubMed ID: 30865484
[TBL] [Abstract][Full Text] [Related]
17. The side-chain epoxidation and hydroxylation of the hepatocarcinogens safrole and estragole and some related compounds by rat and mouse liver microsomes.
Swanson AB; Miller EC; Miller JA
Biochim Biophys Acta; 1981 Apr; 673(4):504-16. PubMed ID: 7225430
[TBL] [Abstract][Full Text] [Related]
18. Study on inter-ethnic human differences in bioactivation and detoxification of estragole using physiologically based kinetic modeling.
Ning J; Louisse J; Spenkelink B; Wesseling S; Rietjens IMCM
Arch Toxicol; 2017 Sep; 91(9):3093-3108. PubMed ID: 28357488
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of 7-ethoxycoumarin, safrole, flavanone and hydroxyflavanone by cytochrome P450 2A6 variants.
Uno T; Obe Y; Ogura C; Goto T; Yamamoto K; Nakamura M; Kanamaru K; Yamagata H; Imaishi H
Biopharm Drug Dispos; 2013 Mar; 34(2):87-97. PubMed ID: 23112005
[TBL] [Abstract][Full Text] [Related]
20. Identification and analysis of the reactive metabolites related to the hepatotoxicity of safrole.
Yang AH; Zhang L; Zhi DX; Liu WL; Gao X; He X
Xenobiotica; 2018 Nov; 48(11):1164-1172. PubMed ID: 29082813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
